Letter: Infliximab de-escalation based on trough levels in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 7, 2015, Pages 939-940

  Paul, S ^a   Roblin, X ^a   Peyrin Biroulet, L ^b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FECES LEVEL; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; LETTER; MINIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; CROHN DISEASE;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940762312     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13335     Document Type: Letter

References (3)

1. Gisbert JP, Marin AC, Chaparro M,. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015; 42: 391-405.
2. Ben-Horin S, Chowers Y, Ungar B, et al,. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther 2015; 42: 356-64.
3. Vande Casteele N., Gils A., Ballet V., et al., Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study [UEGW abstract UEG13-ABS-2468]. United European Gastroenterology Week; October 20-24, 2012. Amsterdam: The Netherlands, 2013.